
|Articles|January 15, 2013
- The Column-01-15-2013
- Volume 9
- Issue 1
"Critical to Quality" Measurements of Protein Aggregation in Biopharmaceuticals
Author(s)Mark Pothecary, Lisa Newey-Keane
In biopharmaceutical development the stability of biological molecules in drug formulations is important. This article describes three different approaches to the measurement and quantification of aggregates in protein solutions, and highlights the range of information that each technique can provide about the sample.
Advertisement
In biopharmaceutical development the stability of biological molecules in drug formulations is important. This article describes three different approaches to the measurement and quantification of aggregates in protein solutions, and highlights the range of information that each technique can provide about the sample.
Articles in this issue
almost 14 years ago
Bugs boost wine aromaalmost 14 years ago
The Elephant in the Roomalmost 14 years ago
EDCs alter US water qualityalmost 14 years ago
"Lean" Approaches to Reduce Waste when Performing Chromatography AnalysisAdvertisement
Related to this article

The panel considers how AI and automation could reshape peptide method development, and why scientific judgment will remain essential.

Piotr Alvarez explains how HILIC complements reversed-phase LC for GLP-1 peptides, and why the field is moving toward MS-friendly TFA alternatives.

Panelists identify the parameters that make or break peptide method robustness and tech transfer, including temperature, flow rate, and dwell volume.

The panel discusses quantitative peptide analysis, including drug substance vs. drug product complexity, recovery, and methionine oxidation risk.

The panel cover protecting peptide recovery, from mobile-phase pH and diluent buffers to inert column hardware.
Advertisement
Advertisement
Trending on LCGC International
1
Prioritizing Unknowns in Nontarget Screening of Food Samples
2
Jan Christensen on Quantitative Non-Targeted Screening
3
Conversations with Michael Dong: Overcoming Challenges with Reversed-Phase Chromatography in Drug Analysis
4
Conversations with Michael Dong: Buffers for Mobile Phase A in Pharmaceutical Analysis
5
